Specify a stock or a cryptocurrency in the search bar to get a summary
Codexis Inc
4QKCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063
Analytics
WallStreet Target Price
27.89 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4QK
Dividend Analytics 4QK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4QK
Stock Valuation 4QK
Financials 4QK
Results | 2019 | Dynamics |